Cell therapies in ovarian cancer.
adoptive cell therapy (ACT)
cancer immunotherapy
neoantigens
ovarian cancer
tumor-infiltrating lymphocyte (TIL)
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2021
2021
Historique:
received:
03
12
2020
accepted:
17
03
2021
entrez:
17
5
2021
pubmed:
18
5
2021
medline:
18
5
2021
Statut:
epublish
Résumé
Epithelial ovarian cancer (EOC) is the most important cause of gynecological cancer-related mortality. Despite improvements in medical therapies, particularly with the incorporation of drugs targeting homologous recombination deficiency, EOC survival rates remain low. Adoptive cell therapy (ACT) is a personalized form of immunotherapy in which autologous lymphocytes are expanded, manipulated
Identifiants
pubmed: 33995591
doi: 10.1177/17588359211008399
pii: 10.1177_17588359211008399
pmc: PMC8072818
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
17588359211008399Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s), 2021.
Déclaration de conflit d'intérêts
Conflict of interest statement: Dr Coukos reports grants from Celgene, grants from Boehringer-Ingelheim, personal fees from Genentech, grants from Roche, personal fees from Roche, grants from BMS, personal fees from BMS, personal fees from AstraZeneca, grants from Iovance Therapeutics, grants from Kite Pharma, personal fees from NextCure, personal fees from Geneos Tx, and personal fees from Sanofi/Avensis outside the submitted work;Dr Coukos has patents in the domain of antibodies and vaccines targeting the tumor vasculature as well as technologies related to T-cell expansion and engineering for T-cell therapy. Dr Coukos holds patents around TEM1 antibodies and receives royalties from the University of Pennsylvania regarding technology licensed to Novartis.Dr Sarivalasis reports consultancy and advisory fees from Roche, Novartis, GSK, Tesaro, BMS, Celgene, BMS, AstraZeneca. Research grants from Roche. Travel fees from Roche, GSK, Tesaro, Clovis, AstraZeneca, MSD, Pfizer, Amgen, Celgene, Novartis.
Références
J Immunother. 2014 Feb-Mar;37(2):115-22
pubmed: 24509174
Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12837-42
pubmed: 17652518
Diagnostics (Basel). 2020 Mar 07;10(3):
pubmed: 32156035
Clin Cancer Res. 2020 Mar 15;26(6):1267-1276
pubmed: 31996390
Cancer Res. 2007 Feb 1;67(3):1317-25
pubmed: 17283169
Oncology (Williston Park). 1995 Oct;9(10):911-21; discussion 922, 924, 926
pubmed: 8573476
Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):5797-802
pubmed: 22454499
Blood. 1998 Feb 1;91(3):756-63
pubmed: 9446633
Nature. 2014 Nov 27;515(7528):577-81
pubmed: 25428507
Science. 2018 Mar 23;359(6382):1355-1360
pubmed: 29567706
Biomedicines. 2016 May 03;4(2):
pubmed: 28536377
J Clin Oncol. 2005 Apr 1;23(10):2346-57
pubmed: 15800326
Semin Immunol. 2014 Apr;26(2):161-72
pubmed: 24618042
Sci Transl Med. 2018 Apr 11;10(436):
pubmed: 29643231
J Immunother. 2008 May;31(4):420-30
pubmed: 18391753
Clin Cancer Res. 2018 Nov 15;24(22):5562-5573
pubmed: 29853601
Cytotherapy. 2014 Feb;16(2):234-44
pubmed: 24438902
Bone Marrow Transplant. 2019 Aug;54(Suppl 2):780-784
pubmed: 31431714
Nat Rev Immunol. 2020 Jan;20(1):25-39
pubmed: 31570880
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
Zhonghua Fu Chan Ke Za Zhi. 1996 Sep;31(9):555-7
pubmed: 9275430
Vaccines (Basel). 2020 Nov 05;8(4):
pubmed: 33167428
Cytotherapy. 2015 Aug;17(8):1130-8
pubmed: 25963952
J Transl Med. 2019 Nov 26;17(1):391
pubmed: 31771601
Onco Targets Ther. 2019 Sep 30;12:8015-8022
pubmed: 31686857
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Nature. 2017 Jul 13;547(7662):217-221
pubmed: 28678778
Cancer Res. 1990 Oct 1;50(19):6302-10
pubmed: 2205379
Cancer Res. 2012 Apr 1;72(7):1844-52
pubmed: 22315351
Lancet. 2019 Mar 23;393(10177):1240-1253
pubmed: 30910306
Cell. 2020 Oct 29;183(3):818-834.e13
pubmed: 33038342
Nat Rev Cancer. 2015 Nov;15(11):668-79
pubmed: 26493647
Curr Opin Biotechnol. 2020 Oct;65:52-59
pubmed: 31927304
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Gynecol Oncol. 2012 Feb;124(2):192-8
pubmed: 22040834
Ann Transl Med. 2016 Jul;4(14):262
pubmed: 27563649
Scand J Immunol. 2020 Oct;92(4):e12917
pubmed: 32557659
N Engl J Med. 1987 Jun 11;316(24):1493-8
pubmed: 3295541
Cell. 2017 Aug 24;170(5):927-938.e20
pubmed: 28841418
Curr Hematol Malig Rep. 2020 Aug;15(4):235-240
pubmed: 32415407
Cancer Treat Res. 1996;82:115-46
pubmed: 8849947
Am Soc Clin Oncol Educ Book. 2020 May;40:1-13
pubmed: 32412818
J Immunother. 2003 Jul-Aug;26(4):332-42
pubmed: 12843795
J Clin Oncol. 1989 Apr;7(4):515-26
pubmed: 2647915
Mol Ther. 2019 Nov 6;27(11):1919-1929
pubmed: 31420241
Cancer Immunol Immunother. 2005 Jun;54(6):587-98
pubmed: 15838708
Sci Transl Med. 2015 Mar 25;7(280):280ps7
pubmed: 25810311
J Immunother. 2012 Feb-Mar;35(2):196-204
pubmed: 22306908
Nat Genet. 2020 Jun;52(6):582-593
pubmed: 32483290
Oncotarget. 2020 Jun 02;11(22):2092-2105
pubmed: 32547707
J Clin Oncol. 1990 Oct;8(10):1618-29
pubmed: 2213099
Immunol Rev. 2019 Jul;290(1):127-147
pubmed: 31355495
Cancer Immunol Immunother. 2002 Mar;51(1):45-52
pubmed: 11845259
J Clin Oncol. 2019 Sep 20;37(27):2460-2471
pubmed: 31403857
Eur J Cancer. 2021 Jan;142:63-82
pubmed: 33221598
Semin Immunopathol. 2019 Jan;41(1):49-58
pubmed: 30187086
Science. 2018 Mar 23;359(6382):1361-1365
pubmed: 29567707
Nat Med. 2019 Jan;25(1):89-94
pubmed: 30510250
Anticancer Res. 1990 May-Jun;10(3):645-53
pubmed: 2142392
Nat Rev Immunol. 2006 May;6(5):383-93
pubmed: 16622476
Cancer Discov. 2019 Aug;9(8):1022-1035
pubmed: 31164343
BJOG. 2012 Jan;119(2):134-6
pubmed: 22168761
Science. 2014 May 9;344(6184):641-5
pubmed: 24812403
Adv Cancer Res. 2019;143:63-144
pubmed: 31202363
Int J Mol Sci. 2019 Jun 15;20(12):
pubmed: 31208030
J Clin Oncol. 2007 Sep 20;25(27):4187-93
pubmed: 17698804
Trends Pharmacol Sci. 2016 Mar;37(3):220-230
pubmed: 26705086
Nat Med. 2013 Jun;19(6):747-52
pubmed: 23644516
Clin Cancer Res. 2014 Jul 1;20(13):3401-10
pubmed: 24987109
Cancer Cell. 2020 Oct 12;38(4):454-472
pubmed: 32822573
Oncoimmunology. 2018 Sep 26;7(12):e1502905
pubmed: 30524900
Cancer Res. 1994 Jan 1;54(1):190-6
pubmed: 8261438
Cell. 2018 Jun 14;173(7):1755-1769.e22
pubmed: 29754820
Cytotherapy. 2014 Aug;16(8):1117-20
pubmed: 24831841
Oncoimmunology. 2013 Jan 1;2(1):e22664
pubmed: 23482679
Semin Immunol. 2010 Jun;22(3):132-43
pubmed: 20356763
Clin Cancer Res. 2013 Sep 1;19(17):4801-15
pubmed: 23838316
Cancer Immunol Immunother. 2012 May;61(5):629-41
pubmed: 22021066
Cancer Immunol Res. 2016 Mar;4(3):215-24
pubmed: 26787822
Nat Commun. 2018 Mar 15;9(1):1092
pubmed: 29545564
J Clin Oncol. 2013 Nov 10;31(32):e439-42
pubmed: 24043743
Front Immunol. 2019 Aug 09;10:1782
pubmed: 31456796
Cancer Res. 2003 Sep 15;63(18):6076-83
pubmed: 14522938
Cancer Res. 2012 Mar 1;72(5):1081-91
pubmed: 22237626
Vaccines (Basel). 2020 Jun 02;8(2):
pubmed: 32498431
Ann Oncol. 1999 Oct;10(10):1145-61
pubmed: 10586330
Ann Oncol. 2019 Dec 1;30(12):1902-1913
pubmed: 31566658
J Immunother Emphasis Tumor Immunol. 1994 Oct;16(3):198-210
pubmed: 7834119
J Immunother. 2004 Jan-Feb;27(1):60-72
pubmed: 14676634
J Clin Invest. 2019 Mar 1;129(3):1109-1114
pubmed: 30714987
Int Rev Immunol. 2011 Apr-Jun;30(2-3):150-82
pubmed: 21557641
Nat Genet. 2019 Dec;51(12):1732-1740
pubmed: 31740835
Ann Oncol. 2020 Sep;31(9):1148-1159
pubmed: 32569725
Clin Cancer Res. 2014 Mar 1;20(5):1125-34
pubmed: 24323902
Cytotherapy. 2011 Jan;13(1):98-107
pubmed: 20849361
Immunotherapy. 2015;7(5):473-6
pubmed: 26065472
Nat Med. 2015 Jan;21(1):81-5
pubmed: 25531942
Discov Med. 2015 Sep;20(109):97-109
pubmed: 26463091
EBioMedicine. 2020 Sep;59:102975
pubmed: 32853984
Lancet Oncol. 2020 Oct;21(10):e463-e476
pubmed: 33002442
Br J Cancer. 2019 Feb;120(4):424-434
pubmed: 30718808
Cancer Res. 2019 Jan 15;79(2):387-396
pubmed: 30482775
Gynecol Oncol. 2017 Jun;145(3):420-425
pubmed: 28392127
Cancer Immunol Res. 2018 May;6(5):605-616
pubmed: 29588319
Cancer Cell. 2017 Mar 13;31(3):311-325
pubmed: 28292435
J Immunol. 2015 Dec 1;195(11):5117-22
pubmed: 26589749
Nat Rev Clin Oncol. 2020 Mar;17(3):147-167
pubmed: 31848460
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15
pubmed: 17062687
Cancer Res. 1991 Apr 1;51(7):1934-9
pubmed: 2004379
Mol Ther. 2020 Nov 4;28(11):2320-2339
pubmed: 32979309
J Clin Oncol. 2016 Nov 1;34(31):3787-3795
pubmed: 27269940
Science. 2015 Apr 3;348(6230):62-8
pubmed: 25838374
J Transl Med. 2013 Jun 18;11:149
pubmed: 23777306
Ann Intern Med. 2000 Oct 3;133(7):504-15
pubmed: 11015163
Clin Cancer Res. 1995 May;1(5):501-7
pubmed: 9816009
Clin Cancer Res. 2016 Apr 15;22(8):1875-84
pubmed: 27084741
Nat Biomed Eng. 2018 Jun;2(6):377-391
pubmed: 31011197
Virchows Arch. 2019 Apr;474(4):449-461
pubmed: 30470934
Science. 2020 Feb 28;367(6481):
pubmed: 32029687
Nat Med. 2019 Oct;25(10):1488-1499
pubmed: 31591590
J Transl Med. 2015 Mar 28;13:102
pubmed: 25890361
Vaccines (Basel). 2015 Apr 23;3(2):344-72
pubmed: 26343191
Oncoimmunology. 2020 Jul 11;9(1):1792058
pubmed: 32923156
Nature. 2020 Apr;580(7805):640-646
pubmed: 32350471
Clin Cancer Res. 2000 Jun;6(6):2268-78
pubmed: 10873077